Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Portfolio Pulse from
Athira Pharma has released its Q3 2024 financial results and provided updates on its pipeline. The company expects to complete a Phase 1 clinical study of ATH-1105 by the end of the year and plans to start dosing ALS patients in 2025.
November 07, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Athira Pharma announced its Q3 2024 financial results and updates on its drug pipeline. The company is on track to complete a Phase 1 study of ATH-1105 by year-end and plans to start dosing ALS patients in 2025.
The completion of the Phase 1 study and the plan to start dosing ALS patients in 2025 are positive developments for Athira Pharma, indicating progress in their drug pipeline. This could lead to increased investor confidence and a potential positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100